Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid(Queen Mary University of London), Joyce O’Shaughnessy(Baylor University Medical Center), Heather L. McArthur(Southwestern Medical Center), Masato Takahashi(National Hospital Organization Hokkaido Medical Center), Peter A. Fasching(Universitätsklinikum Erlangen), Lajos Pusztai(Yale University), Fátima Cardoso(Breast Cancer Alliance), Nadia Harbeck(Breast Center), Gursel Aktan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carsten Denkert(Philipps University of Marburg), Javier Cortés(Villa Maria Hospital), Rebecca Dent(Duke-NUS Medical School), Theodoros Foukakis(Karolinska Institutet), Jonas Bergh(Karolinska Institutet), Vassiliki Karantza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jing Zhao(Lee's Pharmaceutical (China)), Yeon Hee Park(Samsung Medical Center), Sherko Kümmel(Kliniken Essen-Mitte), Michael Untch(Helios Kliniken), Liyi Jia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rina Hui(The University of Sydney)
Cited by 3,098
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
|Circulation|2017|3.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Prevention of Infective Endocarditis
|Circulation|2007|2.8k